(Q42677733)

English

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response

scientific article published on 14 August 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 November 2017

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response (English)

1 reference

Europe PubMed Central

4 November 2017

phase III clinical trial

0 references

multicenter clinical trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Serena Di Cosimo

5

1 reference

Europe PubMed Central

4 November 2017

Chiun-Sheng Huang

object named as

Chiun-Sheng Huang

18

0 references

Evandro de Azambuja

object named as

Evandro de Azambuja

1

0 references

7

object named as

Michael Untch

1 reference

Europe PubMed Central

4 November 2017

14

object named as

Edith A Perez

1 reference

Europe PubMed Central

4 November 2017

Peter Vuylsteke

19

object named as

Peter Vuylsteke

1 reference

Europe PubMed Central

4 November 2017

author name string

Andrew P Holmes

2

1 reference

Europe PubMed Central

4 November 2017

Martine Piccart-Gebhart

3

1 reference

Europe PubMed Central

4 November 2017

Eileen Holmes

4

1 reference

Europe PubMed Central

4 November 2017

Ramona F Swaby

6

1 reference

Europe PubMed Central

4 November 2017

Christian Jackisch

8

1 reference

Europe PubMed Central

4 November 2017

Istvan Lang

9

1 reference

Europe PubMed Central

4 November 2017

Ian Smith

10

1 reference

Europe PubMed Central

4 November 2017

Frances Boyle

11

1 reference

Europe PubMed Central

4 November 2017

Binghe Xu

12

1 reference

Europe PubMed Central

4 November 2017

Carlos H Barrios

13

1 reference

Europe PubMed Central

4 November 2017

Hatem A Azim

15

1 reference

Europe PubMed Central

4 November 2017

Sung-Bae Kim

16

1 reference

Europe PubMed Central

4 November 2017

Sherko Kuemmel

17

1 reference

Europe PubMed Central

4 November 2017

Ruey-Kuen Hsieh

20

1 reference

Europe PubMed Central

4 November 2017

Vera Gorbunova

21

1 reference

Europe PubMed Central

4 November 2017

Alexandru Eniu

22

1 reference

Europe PubMed Central

4 November 2017

Lydia Dreosti

23

1 reference

Europe PubMed Central

4 November 2017

Natalia Tavartkiladze

24

1 reference

Europe PubMed Central

4 November 2017

Richard D Gelber

25

1 reference

Europe PubMed Central

4 November 2017

Holger Eidtmann

26

1 reference

Europe PubMed Central

4 November 2017

José Baselga

27

1 reference

Europe PubMed Central

4 November 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

14 August 2014

1 reference

Europe PubMed Central

4 November 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

4 November 2017

15

1 reference

Europe PubMed Central

4 November 2017

10

1 reference

Europe PubMed Central

4 November 2017

1137-1146

1 reference

Europe PubMed Central

4 November 2017

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970320-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970320-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970320-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970320-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant trastuzumab in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970320-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970320-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970320-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970320-1

7 January 2021

based on heuristic

inferred from DOI database lookup

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970320-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970320-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Importance of events per independent variable in proportional hazards analysis. I. Background, goals, and general strategy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970320-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970320-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Challenges of guarantee-time bias

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970320-1

7 January 2021

based on heuristic

inferred from DOI database lookup

THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970320-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970320-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970320-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970320-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970320-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970320-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970320-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970320-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970320-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970320-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970320-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970320-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970320-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(14)70320-1

1 reference

Europe PubMed Central

4 November 2017

1 reference

Europe PubMed Central

4 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42677733&oldid=2046288290"